At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 120 enrolled
Drug / intervention
PLN-74809 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-blind, Dose-ranging, Placebo Controlled Phase 2a Evaluation of the Safety, Tolerability and Pharmacokinetics of PLN-74809 in Participants With Idiopathic Pulmonary Fibrosis (INTEGRIS-IPF)
In Brief
A Phase 2 clinical trial evaluating PLN-74809 and Placebo for Idiopathic Pulmonary Fibrosis. Completed, enrolled 120 participants across 20 sites in 7 countries.
Detailed Summary
A Phase 2a, multicenter, 4-part, randomized, double-blind, dose-ranging, placebo-controlled study to evaluate the safety, tolerability, and PK of once-daily treatment with PLN-74809 in participants with idiopathic pulmonary fibrosis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsIdiopathic Pulmonary Fibrosis
CountriesAustralia, Belgium, Canada, Italy, Netherlands, New Zealand, United States
Collaborators--
Timeline
Phase 2CompletedFinished
2020202120222023202420252026
Enrollment StartMar 2020
First PostedMay 2020
Primary CompletionFeb 2023
Study CompletionFeb 2023
TodayJul 2026
First PostedMay 21, 2020
Enrollment StartMar 3, 2020
Primary CompletionFeb 1, 2023
Study CompletionFeb 15, 2023
TodayJul 2, 2026
Enrollment to primary: 2.9 yearsPosted 6.1 years ago
Interventions
PLN-74809drug
PLN-74809
Placebodrug
Placebo